Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer
FOR46 (FG-3246) 是一种靶向 CD46 的免疫调节抗体药物偶联物，用于治疗转移性去势抵抗性前列腺癌患者，这是一项 I 期首次人体研究。
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-24-01989
Aggarwal, Rahul R; Vuky, Jacqueline; VanderWeele, David; Rettig, Matthew; Heath, Elisabeth I; Quigley, David; Huang, Jiaoti; Chumber, Arun; Cheung, Alexander; Foye, Adam; Leung, Stanley; Abbey, Jill; Dorr, Andrew; Nasoff, Marc; Hunter, John; Wang, Steven; Flavell, Robert R; Fong, Lawrence; Liu, Bin; Small, Eric J
肿瘤
T细胞
肿瘤免疫
CD46
Human
前列腺癌
CD4
免疫/内分泌
